Bristol-Myers Squibb Company (JOBS) Announces Filing of IPO Registration Statement of Its Wholly-owned Subsidiary
Published: Sep 16, 2008
In April 2008, Bristol-Myers Squibb Company announced it would file a registration statement by the end of 2008 to sell approximately 10 percent and no more than 20 percent of Mead Johnson Nutrition Company stock to the public through an IPO. Bristol-Myers Squibb intends to retain at least an 80 percent equity interest in Mead Johnson Nutrition Company for the foreseeable future. The IPO process is expected to be completed by the end of the first half of 2009.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted before the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The statements in this press release that are not historical facts may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different.
Citi and Morgan Stanley will be acting as joint book-running managers for the proposed offering. A written prospectus meeting the requirements of Section 10 of the Securities Act of 1933, when available, may be obtained from: Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220, Attention: Prospectus Department, telephone (800) 831-9146, or by emailing email@example.com or Morgan Stanley & Co. Incorporated, 180 Varick Street, 2nd Floor, New York, New York, 10014, Attention: Prospectus Department, telephone (866) 718-1649, or by emailing firstname.lastname@example.org.
Bristol-Myers Squibb Company is a global biopharmaceutical company whose mission is to extend and enhance human life.
Contact: Bristol-Myers Squibb Company Media: Brian Henry, 609-252-3337 email@example.com or Investors: John Elicker, 212-546-3775 firstname.lastname@example.org
Source: Bristol-Myers Squibb Company